<DOC>
	<DOCNO>NCT00252044</DOCNO>
	<brief_summary>Hypothesis : Schizotypal personality disorder patient show cognitive improvement 1 ) work memory 2 ) learn memory 3 ) sustain attention 4 ) enhance performance AX-CPT , N-back Eriksen pergolide treatment . There significant diagnosis drug administration 0.3 mg oral pergolide interaction performance cognitive task , schizotypal personality disorder group demonstrate significantly improve peformance compare personality disorder group pergolide compare placebo . Design : Randomized , double-blind , crossover study pergolide vs. placebo . Half subject receive pergolide eight week ; half subject receive placebo four week follow pergolide four week .</brief_summary>
	<brief_title>Pergolide Cognitive Symptoms Schizotypal Personality Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Neurobehavioral Manifestations</mesh_term>
	<mesh_term>Schizotypal Personality Disorder</mesh_term>
	<mesh_term>Pergolide</mesh_term>
	<criteria>DSMIV criterion Schizotypal Personality Disorder ( meet full criterion bar one ) another personality disorder show impairment marker cognitive functioning . Medically healthy , abuse drug alcohol , least two week medicationfree significant neurological disease . DSMIV RDC criterion Schizophrenia Schizophreniarelated psychotic disorder Bipolar Disorder . Any Axis I disorder must transient preceded personality disorder diagnosis , primarily responsible subject â€™ functional impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>